BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

391 related articles for article (PubMed ID: 25919147)

  • 21. Overexpression and nuclear translocation of hypoxia-inducible factor prolyl hydroxylase PHD2 in head and neck squamous cell carcinoma is associated with tumor aggressiveness.
    Jokilehto T; Rantanen K; Luukkaa M; Heikkinen P; Grenman R; Minn H; Kronqvist P; Jaakkola PM
    Clin Cancer Res; 2006 Feb; 12(4):1080-7. PubMed ID: 16489060
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HPV status, cancer stem cell marker expression, hypoxia gene signatures and tumour volume identify good prognosis subgroups in patients with HNSCC after primary radiochemotherapy: A multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG).
    Linge A; Lohaus F; Löck S; Nowak A; Gudziol V; Valentini C; von Neubeck C; Jütz M; Tinhofer I; Budach V; Sak A; Stuschke M; Balermpas P; Rödel C; Grosu AL; Abdollahi A; Debus J; Ganswindt U; Belka C; Pigorsch S; Combs SE; Mönnich D; Zips D; Buchholz F; Aust DE; Baretton GB; Thames HD; Dubrovska A; Alsner J; Overgaard J; Krause M; Baumann M;
    Radiother Oncol; 2016 Dec; 121(3):364-373. PubMed ID: 27913065
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HIF-1α and CA-IX as predictors of locoregional control for determining the optimal treatment modality for early-stage laryngeal carcinoma.
    Kwon OJ; Park JJ; Ko GH; Seo JH; Jeong BK; Kang KM; Woo SH; Kim JP; Hwa JS; Carey TE
    Head Neck; 2015 Apr; 37(4):505-10. PubMed ID: 24677746
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hypoxic modification of radiotherapy in squamous cell carcinoma of the head and neck--a systematic review and meta-analysis.
    Overgaard J
    Radiother Oncol; 2011 Jul; 100(1):22-32. PubMed ID: 21511351
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative analysis of transcriptomics based hypoxia signatures in head- and neck squamous cell carcinoma.
    Tawk B; Schwager C; Deffaa O; Dyckhoff G; Warta R; Linge A; Krause M; Weichert W; Baumann M; Herold-Mende C; Debus J; Abdollahi A
    Radiother Oncol; 2016 Feb; 118(2):350-8. PubMed ID: 26711490
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The relation between hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha expression with anemia and outcome in surgically treated head and neck cancer.
    Winter SC; Shah KA; Han C; Campo L; Turley H; Leek R; Corbridge RJ; Cox GJ; Harris AL
    Cancer; 2006 Aug; 107(4):757-66. PubMed ID: 16826581
    [TBL] [Abstract][Full Text] [Related]  

  • 27. IAEA-HypoX. A randomized multicenter study of the hypoxic radiosensitizer nimorazole concomitant with accelerated radiotherapy in head and neck squamous cell carcinoma.
    Hassan Metwally MA; Ali R; Kuddu M; Shouman T; Strojan P; Iqbal K; Prasad R; Grau C; Overgaard J
    Radiother Oncol; 2015 Jul; 116(1):15-20. PubMed ID: 25913070
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Validation of a 15-gene hypoxia classifier in head and neck cancer for prospective use in clinical trials.
    Toustrup K; Sørensen BS; Metwally MA; Tramm T; Mortensen LS; Overgaard J; Alsner J
    Acta Oncol; 2016; 55(9-10):1091-1098. PubMed ID: 27161763
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High RAB25 expression is associated with good clinical outcome in patients with locally advanced head and neck squamous cell carcinoma.
    Téllez-Gabriel M; Arroyo-Solera I; León X; Gallardo A; López M; Céspedes MV; Casanova I; López-Pousa A; Quer M; Mangues MA; Barnadas A; Mangues R; Pavón MA
    Cancer Med; 2013 Dec; 2(6):950-63. PubMed ID: 24403269
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Epidermal growth factor receptor expression in laryngeal cancer predicts the effect of hypoxia modification as an additive to accelerated radiotherapy in a randomised controlled trial.
    Nijkamp MM; Span PN; Terhaard CH; Doornaert PA; Langendijk JA; van den Ende PL; de Jong M; van der Kogel AJ; Bussink J; Kaanders JH
    Eur J Cancer; 2013 Oct; 49(15):3202-9. PubMed ID: 23867129
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular markers predict outcome in squamous cell carcinoma of the head and neck after concomitant cisplatin-based chemoradiation.
    van den Broek GB; Wildeman M; Rasch CR; Armstrong N; Schuuring E; Begg AC; Looijenga LH; Scheper R; van der Wal JE; Menkema L; van Diest PJ; Balm AJ; van Velthuysen ML; van den Brekel MW
    Int J Cancer; 2009 Jun; 124(11):2643-50. PubMed ID: 19253368
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Microsatellite alterations in head and neck squamous cell carcinoma and relation to expression of pimonidazole, CA IX and GLUT-1.
    De Schutter H; Barbé B; Spaepen M; Begg AC; Balm A; Gregoire V; Haustermans K; Mahy P; Vander Poorten V; Nuyts S
    Radiother Oncol; 2006 Aug; 80(2):143-50. PubMed ID: 16916559
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evolution of treatment and high-risk features in resectable locally advanced Head and Neck squamous cell carcinoma with special reference to extracapsular extension of nodal disease.
    Krstevska V
    J BUON; 2015; 20(4):943-53. PubMed ID: 26416042
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hypoxic regulation of the PERK/ATF4/LAMP3-arm of the unfolded protein response in head and neck squamous cell carcinoma.
    Nagelkerke A; Sweep FC; Stegeman H; Grénman R; Kaanders JH; Bussink J; Span PN
    Head Neck; 2015 Jun; 37(6):896-905. PubMed ID: 24634103
    [TBL] [Abstract][Full Text] [Related]  

  • 35. microRNAs are important players in head and neck carcinoma: a review.
    Janiszewska J; Szaumkessel M; Szyfter K
    Crit Rev Oncol Hematol; 2013 Dec; 88(3):716-28. PubMed ID: 23948550
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The expression of activin receptor-like kinase 1 among patients with head and neck cancer.
    Chien CY; Chuang HC; Chen CH; Fang FM; Chen WC; Huang CC; Huang HY
    Otolaryngol Head Neck Surg; 2013 Jun; 148(6):965-73. PubMed ID: 23447486
    [TBL] [Abstract][Full Text] [Related]  

  • 37. ERCC1 protein expression is associated with differential survival in oropharyngeal head and neck squamous cell carcinoma.
    Patel MR; Zhao N; Ang MK; Stadler ME; Fritchie K; Weissler MC; Zanation AM; Harris SL; Funkhouser WK; Olshan AF; Shores CG; Hayes DN
    Otolaryngol Head Neck Surg; 2013 Oct; 149(4):587-95. PubMed ID: 23846458
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dynamics of tumor hypoxia assessed by 18F-FAZA PET/CT in head and neck and lung cancer patients during chemoradiation: possible implications for radiotherapy treatment planning strategies.
    Bollineni VR; Koole MJ; Pruim J; Brouwer CL; Wiegman EM; Groen HJ; Vlasman R; Halmos GB; Oosting SF; Langendijk JA; Widder J; Steenbakkers RJ
    Radiother Oncol; 2014 Nov; 113(2):198-203. PubMed ID: 25434768
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combination antiangiogenic therapy and radiation in head and neck cancers.
    Hsu HW; Wall NR; Hsueh CT; Kim S; Ferris RL; Chen CS; Mirshahidi S
    Oral Oncol; 2014 Jan; 50(1):19-26. PubMed ID: 24269532
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hypoxia promotes migration/invasion and glycolysis in head and neck squamous cell carcinoma via an HIF-1α-MTDH loop.
    Zhu G; Peng F; Gong W; She L; Wei M; Tan H; Chen C; Zhang D; Li G; Huang D; Zhang X; Liu Y
    Oncol Rep; 2017 Nov; 38(5):2893-2900. PubMed ID: 28901527
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.